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Abstract
Interstitial lung diseases (ILDs) are heterogeneous disorders, involving a large number of conditions, the 
approach to which continues to pose an enormous challenge for pulmonologists. The 2012 Brazilian Thoracic 
Association ILD Guidelines were established in order to provide Brazilian pulmonologists with an instrument 
that can facilitate the management of patients with ILDs, standardizing the criteria used for the diagnosis of 
different conditions and offering guidance on the best treatment in various situations. The objective of this 
article was to briefly describe the highlights of those guidelines.
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Resumo
As doenças pulmonares intersticiais (DPIs) são afecções heterogêneas, envolvendo um elevado número de 
condições, cuja abordagem ainda é um grande desafio para o pneumologista. As Diretrizes de DPIs da Sociedade 
Brasileira de Pneumologia e Tisiologia, publicadas em 2012, foram estabelecidas com o intuito de fornecer 
aos pneumologistas brasileiros um instrumento que possa facilitar a abordagem dos pacientes com DPIs, 
padronizando-se os critérios utilizados para a definição diagnóstica das diferentes condições, além de orientar 
sobre o melhor tratamento nas diferentes situações. Esse artigo teve como objetivo descrever resumidamente 
os principais destaques dessas diretrizes.
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among health professionals; to facilitate the 
development of epidemiological registries and 
clinical trials; and, first and foremost, to improve 
patient management. Figure 1 shows the ILD 
classification, the highlights of which are as 
follows:
•	the inclusion of smoking-related diseases, 
including smoking-associated fibrosis 
and combined pulmonary fibrosis and 
emphysema(1-3)
•	the inclusion of bronchiolocentric interstitial 
pneumonia in the group of idiopathic 
interstitial pneumonias(4,5)
•	the creation of a group of lymphoid diseases, 
characterized by lymphocyte proliferation(6)
Noninvasive diagnostic tests
In addition to detailed clinical examination and 
careful occupational history taking, emphasis was 
placed on noninvasive diagnostic tests, including 
chest X-ray, chest CT, pulmonary function tests, 
and exercise tests, the highlights of which are 
summarized below.
Patients with ILD can have normal chest X-rays. 
Therefore, the ILD guidelines emphasize the 
importance of examining chest X-rays for lung 
volumes, disease pattern, and disease distribution, 
as well as for extrapulmonary findings. In addition, 
it is essential that all previous X-rays be reviewed 
to determine whether the disease has progressed 
or become stable.(7) Chest HRCT, which should be 
performed during inhalation and exhalation, is 
described as playing a crucial role in the differential 
diagnosis of ILDs. In addition, when associated 
with the clinical and functional profile, chest 
HRCT findings can play a decisive role in the 
diagnosis of ILD. In patients with ILD, the most 
common HRCT patterns are the septal, reticular, 
cystic, nodular, ground-glass, and consolidation 
patterns.(8-10)
The guidelines describe the major functional 
changes observed in patients with ILD. The pattern 
that is classically associated with ILDs is a restrictive 
pattern, with decreased DLCO. Determination 
of DLCO is the most sensitive test, DLOC being 
often the first to be affected in ILD patients. 
Reductions in SpO2 can be observed at rest and 
during exercise.(11-13) Cardiopulmonary exercise 
testing and the six-minute walk test are the 
main methods for evaluating ILD patients during 
exercise. However, we should bear in mind that 
exercise limitation has a multifactorial origin, 
Introduction
Interstitial lung diseases (ILDs) are 
heterogeneous disorders, involving a large number 
of conditions, the approach to which continues to 
pose an enormous challenge for pulmonologists. 
In view of similarities in presentation, various 
forms of bronchiolitis are included in this group, 
as are alveolar filling disorders and pulmonary 
vasculitis.
The diagnosis of ILD is often delayed, largely 
because of a lack of knowledge on the part of 
health professionals and because of a lack of 
local resources. The prognosis and treatment 
of ILDs vary. In addition, no pharmacological 
treatment can change the course of certain 
ILDs. One of the major factors limiting the care 
provided to ILD patients in Brazil is the small 
number of health facilities with an appropriate 
multidisciplinary team, given that it is essential 
that expert pulmonologists, radiologists, and 
pathologists participate in the evaluation of 
patients with ILDs. In this context, the Brazilian 
Thoracic Association (BTA) Guidelines for ILDs 
were established in order to provide Brazilian 
pulmonologists with an instrument that can 
facilitate the management of patients with ILDs, 
standardizing the criteria used for the diagnosis of 
various pathologies and offering guidance on the 
best treatment in various situations. The objective 
of the present article was to briefly describe the 
highlights of the 2012 BTA Guidelines for ILDs.
Methods
One group of Brazilian experts with recognized 
experience in the treatment of ILDs was convened 
to develop ILD guidelines. An updated review 
of the major articles on ILD was carried out 
by searching the Medline, SciELO, and LILACS 
databases. An attempt was made to find the best 
available evidence, and the review was supported 
by the opinion of the expert panel. After all of 
the material was delivered, a final review was 
performed by all of the authors. The highlights 
of the 2012 BTA Guidelines for ILDs are herein 
divided into topics.
Classification of ILDs
A classification of ILDs was established in order 
to group the diseases by clinical, radiological, and 
histological criteria; to facilitate communication 
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the appearance and cellular profile of the BAL 
fluid, as well as the presence of neoplastic cells, 
together with screening for infectious agents 
and cytopathic effects. A BAL is most important 
and most likely to aid in diagnosis in cases of 
diseases that present with ground-glass opacities, 
consolidations, and nodules on HRCT, such as 
sarcoidosis, hypersensitivity pneumonitis (HP), 
pulmonary alveolar proteinosis (PAP), alveolar 
hemorrhage, acute diffuse lung disease, eosinophilic 
lung disease, and infection.(14,15)
Regarding biopsies, the ILD guidelines 
emphasize that the decision of whether to perform 
TBB or surgical biopsy in ILD patients should take 
into account the clinical evaluation, including 
patient age, occupational history, and functional 
status, as well as the location and CT features 
of the lesions. The yield of TBB is higher than 
is that of BAL in cases of diseases that present 
with ground-glass opacities, consolidations, 
including ventilatory, cardiovascular, and peripheral 
factors. In ILD patients, the main objectives of 
functional evaluation at rest and during exercise 
include detecting airflow limitation in a timely 
manner and facilitating the differential diagnosis, 
as well as determining disease severity, treatment 
response, and prognosis.(12,13) Other tests can be 
performed on the basis of clinical suspicion.
Invasive diagnostic tests
The invasive diagnostic tests recommended 
in the ILD guidelines include BAL, transbronchial 
biopsy (TBB), and surgical biopsy. The guidelines 
emphasize that it is essential to correlate invasive 
test results with clinical and radiological findings, 
as well as with ancillary test results. Ideally, 
such correlations should be established by a 
multidisciplinary team including pulmonologists, 
radiologists, and pathologists.
The ILD guidelines emphasize certain aspects 
of BAL in the evaluation of ILD patients, including 
Figure 1 - Interstitial lung disease classification used in the Brazilian Thoracic Association Guidelines for 
Interstitial Lung Diseases.
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•	a better response to corticosteroids and 
immunosuppressants when compared with 
that of UIP
Organizing pneumonia
In addition to a definition of organizing 
pneumonia (OP), the ILD guidelines present the 
major forms of OP, namely primary OP (cryptogenic 
OP) and secondary OP, and their most common 
causes, as well as the most important radiological 
patterns (i.e., consolidations, mass/nodule, and 
reticular opacities).(28-30) Furthermore, the guidelines 
describe the most commonly used diagnostic 
options and emphasize the favorable response 
to corticosteroids in most cases, despite the 
possibility of recurrence.(28,31)
Sarcoidosis
The ILD guidelines describe the concept of 
sarcoidosis and recommend that etiologies for 
granulomatous tissue inflammation be ruled out. 
The guidelines also describe the diagnostic criteria 
for sarcoidosis; the disease is diagnosed on the 
basis of clinical, radiological, and histological 
findings, and tissue confirmation is not always 
necessary.(32)
The ILD guidelines emphasize that TBB is 
the primary method for diagnosing pulmonary 
sarcoidosis, transesophageal endoscopic 
ultrasound-guided and endobronchial 
ultrasound-guided fine-needle aspiration of lymph 
nodes being described as promising tests.(33,34) 
Ophthalmologic examination, cardiac evaluation, 
pulmonary function testing, chest X-ray, HRCT, 
blood workup, serum biochemistry, assessment of 
calcium metabolism, PPD testing, and urinalysis are 
recommended for all patients who have recently 
been diagnosed with sarcoidosis.
With regard to the treatment of sarcoidosis, 
the ILD guidelines state that spontaneous 
remission can occur, treatment being required 
in the following cases: presence of symptoms; 
significant systemic involvement (neurological 
involvement, myocardial involvement, or 
hypercalcemia); and pulmonary involvement with 
significant dysfunction or disease progression 
after a period of observation. In addition, the 
guidelines recommend that corticosteroids be 
used as the treatment of choice in most patients, 
the use of non-steroidal anti-inflammatory drugs, 
such as methotrexate (second-line treatment), 
and nodules on HRCT, especially when there is 
bronchiolar and peribronchiolar involvement.(16,17)
Surgical biopsies can be performed by 
conventional limited thoracotomy (open lung 
biopsy) or by video-assisted thoracoscopy, with 
similar yields in ILD patients.(18) The choice of 
biopsy site should be guided by HRCT, and areas 
of honeycombing should be avoided.(19) Terminal 
lung, severe pulmonary dysfunction, (relative) 
pulmonary hypertension, and high cardiovascular 
risk are contraindications to the procedure.(20) 
Surgical biopsy should not be performed when 
there is a typical clinical and radiological profile, 
when the diagnosis is established by BAL or TBB, 
or when there is stable fibrosing disease with 
minimal repercussions.
Idiopathic pulmonary fibrosis
The diagnostic criteria for idiopathic pulmonary 
fibrosis (IPF), which are primarily based on 
recently published international guidelines, are 
presented, HRCT being given greater weight and 
surgical biopsy being dispensed with if the HRCT 
findings are characteristic of usual interstitial 
pneumonia (UIP). When biopsy is performed, it 
is recommended that a multidisciplinary team 
including pulmonologists, radiologists, and 
pathologists discuss the diagnostic approach.(21)
Various therapeutic studies were reviewed, 
and most showed disappointing results. No 
pharmacological treatment has proven effective in 
changing the course of IPF. Treatment is limited to 
palliative care, management of comorbidities, early 
referral for lung transplantation, and inclusion in 
randomized trials of new drugs. Although drugs 
such as pirfenidone, tyrosine kinase inhibitors, 
and N-acetylcysteine have been reported to have 
favorable prospects, results from ongoing studies 
are awaited.(21-24)
Nonspecific interstitial pneumonia
Regarding nonspecific interstitial pneumonia 
(NSIP), the guidelines emphasize the following(25-27):
•	the two different forms of presentation of 
NSIP (i.e., fibrotic NSIP and cellular NSIP), 
according to the predominance of fibrosis 
or inflammation
•	the need for thorough screening for 
underlying diseases, especially connective 
tissue diseases (CTDs), HP, and drug exposure
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Smoking-related diseases
The major smoking-related ILDs are presented, 
including respiratory bronchiolitis with ILD, 
desquamative interstitial pneumonia, pulmonary 
Langerhans cell histiocytosis, IPF, combined 
pulmonary fibrosis and emphysema, and the 
recently described smoking-related pulmonary 
fibrosis, all of which can often be seen in the 
same patient.(1,3) Smoking-related ILDs have 
varied clinical, functional, radiological, and 
histological presentations, as well as having 
different prognoses. With regard to treatment, 
major emphasis is placed on smoking cessation, 
which can be sufficient to improve the patient’s 
condition.(1,43)
Lymphangioleiomyomatosis
The ILD guidelines describe the diagnostic 
criteria for lymphangioleiomyomatosis, with an 
emphasis on the fact that biopsy is not required 
in all cases.(44) In addition, the guidelines state 
that, in the presence of CT findings characteristic 
of lymphangioleiomyomatosis, serum VEGF-D 
levels constitute an important diagnostic 
criterion, although determination of VEGF-D 
levels is a test that is not widely available.(45) The 
guidelines also state that hormonal blockade (with 
progesterone or gonadotropin-releasing hormone 
analogues) can be used in severe or progressive 
cases (or both).(44,46) Furthermore, the guidelines 
present promising options for the treatment of 
lymphangioleiomyomatosis, including the use 
of doxycycline (a metalloproteinase inhibitor) 
and, mainly, the use of sirolimus (a mammalian 
target of rapamycin inhibitor). However, clinical 
trials are still needed in order to determine the 
actual role of these medications in the treatment 
of the disease.(47,48)
PAP
The ILD guidelines describe the major forms 
of PAP, namely autoimmune PAP (the most 
common form), secondary PAP, and genetic 
PAP, and emphasis is placed on the criteria for 
confirming the diagnosis of the disease, i.e., 
CT findings characteristic of PAP (crazy-paving 
pattern), together with BAL and TBB findings, 
surgical biopsy being rarely required.(49,50) 
Regarding the therapeutic approach to PAP, 
the highlights are whole-lung lavage (current 
azathioprine, leflunomide, TNF-α antagonists, 
and antimalarials, being reserved for special 
cases, such as those in which treatment with 
non-steroidal anti-inflammatory drugs fails and 
those in which there are significant steroid-related 
adverse effects.(32,35)
HP
The most common exposures associated with 
HP are described in the ILD guidelines.(36) In 
addition, the diagnostic criteria for HP are defined, 
more weight being given to CT patterns suggestive 
of HP and to the possibility of confirming the 
diagnosis by BAL and TBB.(37) With regard to 
treatment, the guidelines emphasize the need 
for withdrawal from exposure; corticosteroids, 
which determine a better response mainly in 
the acute and subacute phases can be used.(37)
CTDs
The ILD guidelines state that the CTDs that 
are most prevalent in ILD patients are progressive 
systemic sclerosis, polymyositis/dermatomyositis, 
rheumatoid arthritis, systemic lupus erythematosus, 
Sjögren’s syndrome, and mixed connective 
tissue disease. The predominant patterns are 
NSIP and UIP; less common patterns include 
OP, bronchiolitis, and lymphocytic interstitial 
pneumonia.(38,39) The guidelines emphasize the need 
to be on the alert for extrapulmonary involvement, 
including respiratory muscle involvement and 
esophageal abnormalities, which can lead to 
pulmonary complications. In the initial routine 
evaluation and in the follow-up of CTD patients 
with pulmonary involvement, HRCT and full 
pulmonary function testing, with determination 
of DLCO, are recommended, as is assessment 
of respiratory muscle strength, in the presence 
of disease with possible muscle involvement.(40)
With regard to treatment, the possibility of 
periodic observation, without starting the patient 
on any medication, should always be considered, 
as should the possibility of referral for lung 
transplantation in advanced cases. When there 
is a need for treatment, initial options include 
a low-dose combination of cyclophosphamide 
and prednisone in cases of progressive systemic 
sclerosis and a corticosteroid with or without 
an immunosuppressant in cases of polymyositis/
dermatomyositis.(41,42)
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the need for early referral of patients to lung 
transplantation centers, especially those patients 
with idiopathic interstitial pneumonia, given 
that transplantation is one of the few treatment 
modalities that have an impact on survival.(60,61)
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